Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Organisation › Details

CureVac AG

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on Messenger RNA (mRNA). The company has more than 15 years of expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipeline and IP portfolio in the industry. The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. Since its inception, CureVac has received approximately $330 million (€300 million) in equity investments. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, the Bill & Melinda Gates Foundation and IAVI. In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year. *

 

Period Start 2015-11-02 renamed (reorg)
  Group CureVac (Group)
  Predecessor CureVac GmbH
Products Industry RNAi technology
  Industry 2 RNActive® vaccination technology
Persons Person Hoerr, Ingmar (CureVac 200601 CEO + co-founder)
  Person 2 von Bohlen, Friedrich (Dievini before Lion Bioscience)
     
Region Region Tübingen
  Country Germany
  Street 15 Paul-Ehrlich-Str.
  City 72076 Tübingen
  Tel +49-7071-92053-0
    Address record changed: 2015-11-05
     
Basic data Employees D: 101 to 500 (2017-10-26)
     
    * Document for �About Section�: Evotec AG. (10/5/15). "Press Release: Evotec Awarded Multi-year Contract to Manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center". Hamburg.
     
   
Record changed: 2018-12-07

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top